Asset Manager

Updated:

Asclepius Life Sciences

Asclepius Life Sciences runs the Asclepius Life Sciences Fund, LP with focus on life sciences venture and buyout deals.

Asclepius Life Sciences logo

Asclepius Life Sciences

Asclepius Life Sciences is a New York-based investment company focused on Buyout strategies. The firm has a team of three staff, including three investment professionals.

General information

Firm type

Generalist

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

New York

Corporate office

New York, NY, United States

Additional offices

Weston, FL, United States

Principals

Stephen C. Glover

Co-Founder and Managing Principal

Michael Levas

Co-Founder and Managing Principal

Dr. Steven Guest

Principal

Sector focus

Healthcare Services

Frequently asked questions

Who runs investment decisions at Asclepius Life Sciences?

Stephen C. Glover and Michael Levas serve as co-founders and managing principals. Dr. Steven Guest acts as principal. Marissa Fayer participates as a business partner with board roles at portfolio companies.

Does Asclepius Life Sciences participate in fund commitments or only direct deals?

The firm operates the Asclepius Life Sciences Fund, LP. Available records show both venture commitments and direct involvement through SPAC structures such as Larkspur Health Acquisition Corp.

Where does the underlying wealth come from?

No public disclosure identifies the source of capital for the Asclepius Life Sciences Fund, LP.

What investment stages does Asclepius Life Sciences typically target?

Records list buyout, early-stage seed, start-up, expansion, and general venture activity.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More New York Generalist profiles